Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo.Lu.Pa.NET: Neoadjuvant 177Lu-DOTATATE PRRT Followed by Surgery for Resectable Pancreatic Neuroendocrine Tumors
2019-002196-34Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jun 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in islet cell tumor, sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Postoperative 90-day morbidity and mortality rate. Started Jun 2021; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2019-002196-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002196-34.